MIGENIX Inc. To Participate In "Breakthroughs In Hepatitis" Focus Session At The Biotechnology Industry Organization (BIO) CEO & Investor Conference In New York City

VANCOUVER, BC, and SAN DIEGO, CA, Feb. 13 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, has been selected to participate in the "Breakthroughs in Hepatitis" focus session at the 8th Annual BIO CEO & Investor Conference in New York City, February 14th and 15th. Dr. James DeMesa, President and CEO of MIGENIX, will join other panelists to review the next generation of potential hepatitis breakthroughs, and will present MIGENIX's celgosivir (MX-3253), a first-in-class alpha glucosidase 1 inhibitor for the treatment of chronic Hepatitis C infections. The panel discussion and presentations will start at 9am ET Tuesday, February 14, 2006 in the Louis XVI Suite Center/West of the Waldorf-Astoria hotel in New York City. A web cast of the focus session will be available at http://ceo.bio.org/opencms/ceo/2006/index.jsp by February 16, 2006 and will also be accessible at www.migenix.com when available.

About Celgosivir

MX-3253 (celgosivir) is an alpha-glucosidase I inhibitor in Phase II development and is currently the only oral anti-HCV drug in clinical development which acts through this mechanism of action. Alpha-glucosidase is a host enzyme essential for the proper folding of the E1 and E2 HCV envelope proteins. Inhibition of this enzyme results in prevention of viral replication and release from the cell. In preclinical studies, celgosivir has demonstrated strong synergy with interferon-alpha with and without ribavirin, as well as with other anti-HCV compounds, and has the potential to be included as part of a combination therapy approach to improve efficacy and/or tolerability.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.

"Jim DeMesa" ------------ James M. DeMesa, M.D. President & CEO CONTACTS Art Ayres Dian Griesel, Ph.D. MIGENIX Inc. Investor Relations Group Tel: (604) 221-9666 Ext. 233 Tel: (212) 825-3210 aayres@migenix.comTheproteam@aol.com The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

MIGENIX Inc.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233,aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel:(212) 825-3210, Theproteam@aol.com; To request a free copy of thisorganization's annual report, please go to http://www.newswire.ca and clickon Tools for Investors.

Back to news